Prokarium and Probiomed initiated their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks. The first vaccine to be manufactured will be developed to prevent so-called ‘Montezuma’s revenge’ or diarrhea, which affects the local population as well travelers in Mexico and many countries.   The leading bacterial causes of diarrhea are Shigella, enterotoxigenic E. coli (ETEC) and Non-Typhoidal Salmonellosi...